irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $5.64MPUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.
- #2 $852KBUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.
named programs · 5 · from sources
What they call their work
1×1 Vision
Strategic initiative aiming for one-month treatment for active TB and one-day treatment for latent TB infection through development of new drugs and long-acting injectables.
BPaL/M Regimen
Six-month, all-oral treatment for drug-resistant tuberculosis, designed to replace longer, more toxic regimens.
Fast Track the Cure
Advocacy and shared learning initiative to accelerate access to new TB treatments and support country adoption.
PeerLINC
Peer-to-peer technical assistance model supporting implementation of new TB regimens in high-burden countries.
Upskill TB
Digital training platform to enhance health worker capacity in TB diagnosis and treatment.
activities · 1 group
What they do
-
Global Tuberculosis Drug Development and Access 11 activities
- Advocating for adoption and affordability of new TB treatmentsAdvocates for public and private engagement in TB research and negotiates for the adoption, availability, and affordability of new anti-TB drugs in high-need regions. Provides strategic advice through the Access Advisory Committee and Global TB Stakeholders committee on R&D, access, fundraising, and global information sharing.
- Conducting clinical research and trials for new TB treatmentsConducted pivotal clinical trials including the NC-009 Phase 2 trial evaluating sorfequiline and the SPaL regimen, and evaluated a three-drug, all-oral six-month regimen that achieved approximately 89% treatment success. Also developed the first-ever FDA-approved treatment for highly drug-resistant tuberculosis.
- Developing and deploying BPaL/M regimen for drug-resistant TBDeveloped a new three-drug, all-oral, six-month regimen (BPaL/M) for drug-resistant TB with treatment success rates comparable to those for drug-sensitive TB. The regimen has saved an estimated 11,000–20,000 lives and $100–160 million to date, with projections to save 191,000 lives and $1.29 billion by 2034 while treating nearly 2 million people.
- Developing and managing a pipeline of new tuberculosis drugsManages the largest research pipeline of new tuberculosis drugs in history, focusing on addressing treatment challenges for drug-resistant TB through innovation in drug development. This includes building a robust portfolio of drug candidates and transforming the TB drug development process.
- Developing child-friendly TB treatmentsDeveloped child-friendly formulations for drug-sensitive tuberculosis to improve treatment access and adherence among pediatric populations.
- Enabling national adoption of BPaL/M as default treatmentEnabled implementation of the BPaL/M regimen as the default treatment for eligible patients in high-burden countries including Indonesia, Pakistan, Peru, Philippines, South Africa, and Ukraine.
- Facilitating global procurement and affordability of pretomanidFacilitated the procurement of 246,000 courses of pretomanid across more than 110 countries by 2025 and increased affordability through generic competition, reducing the price by 33% to $0.88 per tablet.
- Negotiating agreements to advance equitable access to TB drugsNegotiates, implements, and manages global agreements with public and private organizations to support the development and ensure equitable, affordable access to new anti-TB drugs.
- Providing scientific and technical expertise in TB drug developmentProvides technical guidance on TB drug research, development, manufacturing, and distribution through its Scientific Advisory Committee.
- Securing regulatory approval and global endorsement of new TB drugsSecured global approval and endorsement of pretomanid for use in drug-resistant TB treatment and became the first not-for-profit organization to develop and register an anti-tuberculosis drug in 2019.
- Supporting rollout of new TB treatments through training and technical assistanceSupported the rollout of BPaL/M in high-burden countries such as India, Brazil, and China through expert training programs in 2025. Also provides ongoing technical expertise via PeerLINC, a peer-to-peer support platform, and Upskill TB, a digital training tool to strengthen health system readiness.
-
financials · form 990 · fy2024
revenue
Total revenue$63.73M
Contributions & grants$52.74M83%
Program service revenue$00%
Investment income$9.68M15%
Other revenue$1.32M
expenses
Total expenses$61.51M
Program expenses88%
Admin / overhead9%
Fundraising2%
Salaries & benefits$17.96M
Grants paid out$360K
Largest expense lineCompensation
balance sheet
Total assets$204.32M
Cash$34.38M
Investments$144.82M
Liabilities$28.01M
Net assets$176.31M
Liquid reserves35.0 mo
3 years on record · 2020–2024 · YoY revenue +5.8%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 12
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| DR MELVIN SPIGELMAN | PRESIDENT/CEO | 45 | $1.05M |
| DR NADER FOTOUHI | SR. VP, CHIEF SCIENTIFIC OFFICER | 45 | $684K |
| DR EUGENE SUN | SR. VP, RESEARCH & DEVELOPMENT | 45 | $674K |
| MARIA BEUMONT | VP, CHIEF MEDICAL OFFICER | 45 | $584K |
| COLLEEN PERO | SECRETARY/CAO | 45 | $541K |
| ROBERT LORETTE | SR. VP, BUSINESS DEVELOPMENT | 45 | $536K |
| ANGELA VANDERPLOEG | TREASURER/CFO | 45 | $526K |
| SANDEEP JUNEJA | SR. VP, MARKET ACCESS | 45 | $521K |
| KATHLEEN SCHOSTACK | SR. VP, PROGRAM & ALLIANCE MANAGEMENT | 45 | $519K |
| SALAH FORAIDA | SR. DIRECTOR, MEDICAL AFFAIRS | 45 | $482K |
| PIETRO O TURILLI | SR. VP, EXTERNAL AFFAIRS | 45 | $467K |
| RAJNEESH TANEJA | VP, PHARMACEUTICAL PRODUCT DEVELOPMENT | 45 | $452K |
board members · 11
- AKSHAY VAISHNAW — DIRECTOR (AS OF 12/01/24)
- ANN TAYLOR — DIRECTOR (AS OF 09/01/24)
- ARIEL PABLOS-MENDEZ — VICE-CHAIR
- DAVID NORTON — CHAIR
- ERIC GOOSBY — DIRECTOR
- KIM SCHWARTZ — DIRECTOR
- MITCHELL WARREN — DIRECTOR
- RASHA HIBRI — DIRECTOR
- RATAN WATAL — DIRECTOR
- SRISHTI GUPTA — DIRECTOR (AS OF 12/01/24)
- SUNDAR KODIYALAM — DIRECTOR
relationships · 37
Who they work with
- AbbVie Partner — Dale J. Kempf from AbbVie serves on the Scientific Advisory Committee.
- Anabios Partner — Jack Reynolds from Anabios serves on the Scientific Advisory Committee.
- Bill and Melinda Gates Foundation Funder — Yogan Pillay from the Bill and Melinda Gates Foundation serves on the Access Advisory Committee.
- Clinton Health Access Initiative Partner — David Ripin from Clinton Health Access Initiative serves on the Access Advisory Committee.
- Cornell Medical School Partner — Carl Nathan from Cornell Medical School serves on the Scientific Advisory Committee.
- DNDi Partner — Dale J. Kempf from DNDi serves on the Scientific Advisory Committee.
- Declaration of Cape Town Partner — Co-founded through the roadmap established by the Declaration of Cape Town, which called for the creation of TB Alliance.
- Elizabeth Glaser Pediatric AIDS Foundation Partner — Collaborates through shared leadership in the Global TB Stakeholders group; Dr. Doris Macharia, President of EGPAF, was elected President of the Global TB Stakeholders and joined TB Alliance's Board of Directors.
- Elizabeth Glaser Pediatric AIDS Foundation Partner — President of Global TB Stakeholders is Dr. Doris Macharia, who holds leadership at Elizabeth Glaser Pediatric AIDS Foundation.
- Fast Track the Cure Partner — Partnership to advance advocacy and shared learning for accelerating access to new TB treatments.
- Johns Hopkins Bloomberg School of Public Health Partner — Jaap Broekmans from Johns Hopkins Bloomberg School of Public Health serves on the Access Advisory Committee.
- Johns Hopkins University Partner — Cited TB Alliance's BPaL/M regimen impact data projecting treatment of nearly 2 million people and $1.2B in savings over ten years.
- Johns Hopkins University Partner — Collaborated on modeling exercise to quantify impact of BPaL/M regimens.
- Johns Hopkins University Partner — Collaborated on modeling the impact of BPaL/M regimens, providing projections on lives saved and cost savings from real-world and future data.
- Johns Hopkins University Partner — Conducted research on the impact of the BPaL/M regimen in collaboration with or supported by TB Alliance.
- Johns Hopkins University Partner — Eric Nuermberger from Johns Hopkins University serves on the Scientific Advisory Committee.
- Lgenia Partner — Philip Hipskind from Lgenia serves on the Scientific Advisory Committee.
- Lupin Labs Partner — Third licensee of pretomanid, contributing to increased availability and affordability after achieving WHO pre-qualification.
- Management Sciences for Health (MSH) Partner — Gustavo Do Valle Bastos and Andre Zagorski from Management Sciences for Health serve on the Access Advisory Committee.
- Molbio Diagnostics Partner — K.S. Sachdeva from Molbio Diagnostics serves on the Access Advisory Committee.
- Novartis Partner — Shefali Kakar from Novartis serves on the Scientific Advisory Committee.
- PeerLINC Partner — Collaborates on a peer-to-peer technical assistance model to support implementation of new TB regimens.
- Public and private organizations Partner — Maintains alliances and negotiates agreements with public and private organizations worldwide to support tuberculosis drug development and equitable access.
- Rabin Martin Partner — Jeff Sturchio from Rabin Martin serves on the Access Advisory Committee.
- Survivors Against TB Partner — Saurabh Rane from Survivors Against TB serves on the Access Advisory Committee.
- TB Proof Partner — Zolelwa Sifumba from TB Proof serves on the Access Advisory Committee.
- The Republican Research and Practical Centre for Pulmonology and TB, Belarus Partner — Alena Skrahina from The Republican Research and Practical Centre for Pulmonology and TB, Belarus serves on the Access Advisory Committee.
- The Stop TB Partnership Partner — Suvanand Sahu from The Stop TB Partnership serves on the Access Advisory Committee.
- Upskill TB Partner — Partnership to deliver digital training tools that build health system capacity for adopting new TB treatments.
- World Health Organization Government — Referenced as a source for global TB estimates and data
+ 7 more
strategies · 4
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- AI and Host-Directed Therapy Integration to Compress Drug Development Timelinesmethodology: AI-accelerated drug discovery with host-directed therapiesBy leveraging AI-enabled tools and host-directed therapies, the organization accelerates target and compound discovery because these innovations improve scientific efficiency and expand the therapeutic pipeline beyond traditional pathogen-focused approaches.
- Global Product Development Partnership Model to Accelerate TB Drug Innovation and Accessmethodology: product_development_partnershipBy operating as a product development partnership that coordinates public, private, academic, and philanthropic stakeholders, the organization accelerates TB drug development and equitable access because this collaborative model reduces costs, leverages global expertise, and aligns R&D with real-world adoption needs.
- Multi-Stakeholder Access Planning to Ensure Equitable and Scalable Treatment Rolloutmethodology: multi-stakeholder_access_planningBy engaging diverse global stakeholders—including external experts and institutional partners—during development and rollout, the organization reduces access barriers and strengthens equity in treatment adoption because inclusive planning generates contextually informed strategies and builds coordinated demand.
- Shorter, Simpler, Safer TB Treatments to Improve Adherence and Uptakemethodology: shorter-simpler-treatmentsBy developing shorter, simpler, and safer treatment regimens (e.g., one-month cure for active TB, all-oral six-month regimens for drug-resistant TB), the organization increases treatment adherence, reduces stigma, and improves treatment-seeking behavior because reduced duration and side effects lower personal and systemic barriers to care.